Mode
Text Size
Log in / Sign up
N/A N=42,491

Mentor MemoryGel Post-Approval Study

Breast Reconstruction · Breast Augmentation · Breast Revision

Enrolled (actual)
42,491
Serious AEs
Results posted
Jun 2020
Primary outcome: Primary: Kaplan Meier Estimated Cumulative Incidence of Reported Complications — 0.0; 6.7; 10.8; 11.2 Cumulative Reoperation Events

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Mentor Silicone Gel-Filled Breast Implants (Device); Saline Breast Implants (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Mentor Worldwide, LLC
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Kaplan Meier Estimated Cumulative Incidence of Reported Complications
0.0; 6.7; 10.8; 11.2; 11.7; 12.5
PRIMARY
Kaplan Meier Estimated Cumulative Incidence of Explantation
0; 3.0; 5.0; 5.2; 5.5; 6.0
SECONDARY
Reasons for Reoperations
465; 17; 2; 26; 1; 238

Summary

In November 2006, U.S. Food and Drug Administration (FDA) approved Mentor's MemoryGel silicone gel-filled breast implants for use in women who are undergoing primary or revisional breast augmentation and primary or revisional breast reconstruction surgery. This postapproval study is intended to satisfy one element of FDA's postapproval monitoring requirements. In January 2015, the FDA approved a protocol amendment that limits the scope of data collection for the study to the collection of only secondary procedure/reoperation data for MemoryGel participants.

Eligibility Criteria

Inclusion Criteria

  • Female, age 18 years or older (22 or older for breast augmentation patients)
  • U.S. resident

Exclusion Criteria

  • If a saline participant, current or past, unilateral or bilateral, silicone breast implants
  • Active infection anywhere in her body
  • Existing breast cancer or pre-cancer of the breast without adequate treatment for those conditions
  • Currently pregnant or nursing
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00756652). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search